ACE.ST

Healthcare Biotechnology

Ascelia Pharma AB (publ)

SEK 0.84

+0.02 +2.20% today

Price History

Not enough data

Key Stats

Market Cap

111.90M

Avg Volume

1.63M

EPS

-SEK 0.47

52W High

SEK 3.55

52W Low

SEK 0.46

Div. Yield

0.0%

Valuation

Forward P/E

-6.98

P/B Ratio

1.23

EV/EBITDA

-1.19

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(65.5%)

Return on Assets

(32.9%)

Liquidity & Leverage

Current Ratio

4.11

Quick Ratio

4.01

Debt / Equity

0.01

Total Cash

38.05M

Total Debt

490,000

About

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.